Literature DB >> 16437674

Effect of liniment levamisole on cellular immune functions of patients with chronic hepatitis B.

Ke-Xia Wang1, Li-Hua Zhang, Jiang-Long Peng, Yong Liang, Xue-Feng Wang, Hui Zhi, Xiang-Xia Wang, Huan-Xiong Geng.   

Abstract

AIM: To explore the effects of liniment levamisole on cellular immune functions of patients with chronic hepatitis B.
METHODS: The levels of T lymphocyte subsets and mIL-2R in peripheral blood mononuclear cells (PBMCs) were measured by biotin-streptavidin (BSA) technique in patients with chronic hepatitis B before and after the treatment with liniment levamisole.
RESULTS: After one course of treatment with liniment levamisole, the levels of CD3(+), CD4(+), and the ratio of CD4(+)/CD8(+) increased as compared to those before the treatment but the level of CD8(+) decreased. The total expression level of mIL-2R in PBMCs increased before and after the treatment with liniment levamisole.
CONCLUSION: Liniment levamisole may reinforce cellular immune functions of patients with chronic hepatitis B.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16437674      PMCID: PMC4725075          DOI: 10.3748/wjg.v11.i45.7208

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Prospective randomized study of post-operative chemotherapy with levamisole and UFT for head and neck carcinoma.

Authors:  P Lam; A P Yuen; C M Ho; W K Ho; W I Wei
Journal:  Eur J Surg Oncol       Date:  2001-12       Impact factor: 4.424

2.  Levamisole is a potent enhancer of gilthead seabream natural cytotoxic activity.

Authors:  A Cuesta; M A Esteban; J Meseguer
Journal:  Vet Immunol Immunopathol       Date:  2002-10-28       Impact factor: 2.046

3.  Levamisole induced apoptosis in cultured vascular endothelial cells.

Authors:  M Artwohl; T Hölzenbein; L Wagner; A Freudenthaler; W Waldhäusl; S M Baumgartner-Parzer
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  Immunocompetent cells and lymphocyte reactivity to mitogens in levamisole-treated brain tumor children.

Authors:  T F Hajnzić; M Kastelan; J Lukac; T Hajnzić
Journal:  Pediatr Hematol Oncol       Date:  1999 Jul-Aug       Impact factor: 1.969

5.  Levamisole in steroid-sensitive nephrotic syndrome children with steroid-dependency and/or frequent relapses.

Authors:  L S Fu; C S Chi
Journal:  Acta Paediatr Taiwan       Date:  2000 Mar-Apr

6.  Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance.

Authors:  C Szeto; K M Gillespie; P W Mathieson
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

7.  Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer.

Authors:  F Cafiero; M Gipponi; A Peressini; S Bertoglio; R Lionetto
Journal:  J Surg Oncol       Date:  2000-10       Impact factor: 3.454

8.  Levamisole: adjunctive therapy in steroid dependent minimal change nephrotic children.

Authors:  Ahmed F Donia; Galal M Amer; Hassan A Ahmed; Sanaa H Gazareen; Fatma E Moustafa; Ahmed A Shoeib; Amani M Ismail; Said Khamis; Mohamed A Sobh
Journal:  Pediatr Nephrol       Date:  2002-05       Impact factor: 3.714

9.  Combined interferon alpha with levamisole in patients with metastatic renal cell carcinoma.

Authors:  H Aksoy; S Baltaci; K Türkölmez; I Seçkiner; Y Bedük
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

10.  Levamisole mucosal adjuvant activity for a live attenuated Escherichia coli oral vaccine in weaned pigs.

Authors:  F Bozić; V Bilić; I Valpotić
Journal:  J Vet Pharmacol Ther       Date:  2003-06       Impact factor: 1.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.